Orally active peptides that prevent cell damage and death

US7384908B1 · kind B1 · utility

Assignee

• National Institutes of Health, Office of Technology Transfer · US

Inventors

• Douglas E. Brenneman · North Wales, US
• Catherine Y. Spong · Arlington, US
• Illana Gozes · Ramat HaSharon, IL
• Albert Pinhasov · Beer Sheva, IL
• Eliezer Giladi · Netanya, IL

Key dates

• Filing date: Aug 17, 2000
• Grant date: Jun 10, 2008
• Expiry date: Apr 29, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/185
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. The invention also provides a pharmaceutical composition comprising an ADNF polypeptide comprising an active core site, the active core site comprising at least one D-amino acid. In particular, the pharmaceutical composition of the invention is orally active. The invention further provides methods for reducing neuronal cell death, methods for reducing oxidative stress, and methods for reducing a condition associated with fetal alcohol syndrome using the ADNF polypeptides and the pharmaceutical compositions of the invention.